|
Real-time Estimate
Cboe BZX
18:36:30 08/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 23.34 USD | -4.81% |
|
-7.17% | -1.72% |
| 09-22 | Arcus Biosciences, Inc. Announces New Data for Casdatifan as Treatment for Kidney Cancer Across Multiple Lines of Therapy | CI |
| 09-16 | TD Cowen Initiates Arcus Biosciences at Buy | MT |
| Market Cap | 3.12B 2.79B 2.6B 2.36B 4.45B 302B 4.49B 31.28B 12.22B 154B 11.72B 11.47B 494B | P/E 2026 * |
-6.92x | P/E 2027 * | -6.9x |
|---|---|---|---|---|---|
| Enterprise Value | 2.68B 2.4B 2.24B 2.03B 3.82B 259B 3.85B 26.86B 10.49B 132B 10.07B 9.85B 424B | EV / Sales 2026 * |
34.1x | EV / Sales 2027 * | 59.6x |
| Free-Float |
71.2% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| RCUS | Delayed | |
CBOE
| RCUS | Real-time |
Last Transcript: Arcus Biosciences, Inc.
| 1 day | -4.87% | ||
| 1 week | -7.17% | ||
| Current month | -9.33% | ||
| 1 month | -19.41% | ||
| 3 months | -22.60% | ||
| 6 months | +3.40% | ||
| Current year | -1.72% |
| 1 week | 23.26 |  | 25.58 |
| 1 month | 23.26 | | 29.3 |
| Current year | 18.52 | | 31.74 |
| 1 year | 14.26 | | 31.74 |
| 3 years | 6.5 | | 31.74 |
| 5 years | 6.5 | | 49.1 |
| 10 years | 6.3 | | 49.1 |
| Manager | Title | Age | Since |
|---|---|---|---|
Juan Jaen
PSD | President | 68 | 01/05/2015 |
Terry Rosen
CEO | Chief Executive Officer | 67 | 01/05/2015 |
Robert Goeltz
DFI | Director of Finance/CFO | 53 | 01/08/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Terry Rosen
CHM | Chairman | 67 | 01/12/2017 |
Kathryn Falberg
BRD | Director/Board Member | 65 | 18/09/2017 |
Yasunori Kaneko
BRD | Director/Board Member | 72 | 01/05/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 21/08/26 | Exercice | Controller/Auditor | 8,481 | 0.0067% | ||
| 10/07/26 | Sell | Founder | -20,067 | 0.0160% | ||
| 11/06/26 | Free | Director | 22,600 | 0.0180% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.81% | -7.17% | +55.61% | +42.72% | 3.12B | |
| +4.16% | +4.16% | +49.37% | +94.17% | 74.68B | |
| -14.98% | -15.28% | +3.75% | +52.68% | 58.7B | |
| -2.17% | +0.86% | +3.78% | +31.79% | 48.36B | |
| -8.86% | -10.64% | +284.73% | +622.34% | 43.05B | |
| -1.78% | -2.81% | +26.32% | +26.99% | 42.48B | |
| -5.98% | -4.75% | -2.66% | +97.78% | 41.39B | |
| -0.11% | +1.96% | +9.19% | +52.66% | 31.29B | |
| -2.62% | -4.43% | -12.91% | -15.32% | 23.93B | |
| -3.71% | -10.32% | -39.82% | +297.31% | 22.22B | |
| Average | -4.12% | -2.56% | +37.74% | +130.31% | 38.92B | |
| Weighted average by Cap. | -3.99% | -1.48% | +42.71% | +132.75% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 78.61M 70.24M 65.53M 59.52M 112M 7.6B 113M 787M 308M 3.87B 295M 289M 12.43B | 50.68M 45.28M 42.25M 38.37M 72.27M 4.9B 72.81M 508M 198M 2.49B 190M 186M 8.01B |
| Net income | -446M -399M -372M -338M -637M -43.18B -641M -4.47B -1.75B -21.96B -1.68B -1.64B -70.59B | -443M -395M -369M -335M -631M -42.81B -636M -4.43B -1.73B -21.77B -1.66B -1.63B -69.99B |
| Net Debt | -441M -394M -367M -334M -628M -42.63B -633M -4.41B -1.72B -21.68B -1.65B -1.62B -69.69B | -102M -91.28M -85.16M -77.35M -146M -9.88B -147M -1.02B -400M -5.03B -384M -375M -16.16B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/10/26 | $23.38 | -4.67% | 165,515 |
| 07/10/26 | $24.52 | +0.99% | 1,601,275 |
| 06/10/26 | $24.28 | -1.86% | 824,849 |
| 05/10/26 | $24.74 | +1.23% | 1,390,862 |
| 02/10/26 | $24.44 | -3.13% | 1,041,906 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RCUS Stock
Select your edition
All financial news and data tailored to specific country editions
